Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CET

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
12/15 GLAXOSMITHKLINE : Transfer of Shares out of Treasury
12/14 GLAXOSMITHKLINE : New Organic Research Study Findings Have Been Reported by Rese..
12/14 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Describe Findings in Orga..
12/14 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Have Reported New Data ..
12/14 GLAXOSMITHKLINE : Data on Pre-Trial Research Detailed by Researchers at GlaxoSmi..
12/14 GLAXOSMITHKLINE : GSK achieves approval for Nucala for the treatment of eosinoph..
12/14DJGLAXOSMITHKLINE : GSK Applies for Australian Approval of Malaria Treatment
12/14 GLAXOSMITHKLINE : GSK submits regulatory application for single-dose tafenoquine..
12/13 GLAXOSMITHKLINE : standalone profits reach LE102 m ending June
12/13 GLAXOSMITHKLINE : GSK presents promising new data for priority BCMA asset from i..
More news
News from SeekingAlpha
12/14 GSK submits regulatory application for Tafenoquine for the treatment of Plasm..
12/13 GlaxoSmithKline (GSK) Oncology Investor & Analyst Update - Slideshow
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 FDA OKs expanded use for Glaxo's Nucala; shares up 1%
12/12 Glaxo's lead BCMA ADC candidate shows positive effect in early-stage study
Financials ( GBP)
Sales 2017 30 072 M
EBIT 2017 8 245 M
Net income 2017 3 652 M
Debt 2017 14 293 M
Yield 2017 6,20%
P/E ratio 2017 18,08
P/E ratio 2018 14,64
EV / Sales 2017 2,59x
EV / Sales 2018 2,54x
Capitalization 63 476 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 15,5  GBP
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-17.38%85 328
JOHNSON & JOHNSON24.03%380 546
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759